171 related articles for article (PubMed ID: 35834737)
1. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
3. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
[No Abstract] [Full Text] [Related]
4. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
5. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model.
Strand MA; Eukel H; Frenzel O; Skoy E; Steig J; Werremeyer A
Res Social Adm Pharm; 2020 Sep; 16(9):1248-1254. PubMed ID: 31812501
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later.
Strand MA; Frenzel O
Res Social Adm Pharm; 2024 Jul; 20(7):648-653. PubMed ID: 38627152
[TBL] [Abstract][Full Text] [Related]
7. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
9. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
10. Piloting an opioid callback program in community pharmacies.
Hernandez SE; Gilson AM; Gassman M; Ford JH
J Am Pharm Assoc (2003); 2023; 63(6):1796-1802. PubMed ID: 37574197
[TBL] [Abstract][Full Text] [Related]
11. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
13. Preparing student pharmacists to identify opioid misuse, prevent overdose and prescribe naloxone.
Skoy E; Eukel H; Frenzel J; Werremeyer A
Curr Pharm Teach Learn; 2019 May; 11(5):522-527. PubMed ID: 31171255
[TBL] [Abstract][Full Text] [Related]
14. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
16. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
[TBL] [Abstract][Full Text] [Related]
17. Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population-based time-series analysis.
Antoniou T; Martins D; Campbell T; Tadrous M; Munro C; Leece P; Mamdani M; Juurlink DN; Gomes T
Addiction; 2021 Jun; 116(6):1514-1520. PubMed ID: 33207025
[TBL] [Abstract][Full Text] [Related]
18. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
19. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
Strand MA; Eukel H; Burck S
Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
[TBL] [Abstract][Full Text] [Related]
20. Improving Community Pharmacist-Delivered Care for Patients With Psychiatric Disorders Filling an Opioid Prescription.
Werremeyer A; Frenzel O; Strand MA; Eukel H; Skoy E; Steig J
Psychiatr Serv; 2022 Nov; 73(11):1294-1297. PubMed ID: 35502518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
